By Charlie Conchie LONDON (Reuters) -AstraZeneca’s move to upgrade its listing in the U.S. risks pulling liquidity away from ...

AstraZeneca’s move to upgrade its listing in the U.S. risks pulling liquidity away from London’s stock market and could pave ...

AstraZeneca said on Friday it will sell its diabetes and asthma drugs direct to cash-paying U.S. patients at a discount of up ...

The British company said the direct listing would replace the existing listing of its American depository receipts on the ...

The $230 bln drugmaker will directly list shares in New York. With under half its sales from the US, AstraZeneca may not move ...

Shares of AstraZeneca (NASDAQ: AZN) have jumped more than 10% this week. On Monday, the British drugmaker reported positive results from a clinical study of Enhertu in treating HER2-positive early ...

Thermo Fisher Scientific announced an R&D partnership with AstraZeneca BioVentureHub. Crinetics received FDA approval of Palsonify (paltusotine) to treat acromegaly in adults. The agency approved ...

AstraZeneca saw its share prices jump to a new all-time high on Wednesday, as investors cheered reports that President Donald ...

AstraZeneca shares rallied on Wednesday after the U.K. giant and its Japanese partner said the Food and Drug Administration ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The PPD™ clinical research business of Thermo Fisher Scientific, the world leader in serving science, today announced a new ...

AstraZeneca has announced plans to list shares on the New York Stock Exchange, stoking fears that Britain’s biggest drugmaker ...